Mild Cognitive Impairment Is Not Early Alzheimer's

MCI gets handed over as though it were early Alzheimer's. The numbers show it can go three ways.

What does an MCI diagnosis actually mean?

That cognition has measurably declined from where it used to be, and that day-to-day independence is still intact.

Mild cognitive impairment sits between normal aging and dementia. The decline has to be real enough to show on testing, or to be clearly reported by the person or someone who knows them — but not enough to compromise the ability to manage daily life.

Independence is what separates MCI from dementia. When someone stops being able to manage the medications, the money or the appointments, the label changes.

Clinicians usually describe it along two axes:

• Amnestic MCI, where memory is the affected domain, versus non-amnestic, where the problem is language, attention, visuospatial ability or executive function.
• Single-domain versus multi-domain, meaning how many of those areas are affected.

Amnestic and multi-domain patterns are more often associated with progression to Alzheimer's. Non-amnestic patterns are more mixed, and are more likely to point somewhere other than Alzheimer's.

Does MCI always turn into dementia?

No. Some people with MCI go on to develop dementia, some stay the same, and some return to normal.

A meta-analysis pooling 89 studies with a mean follow-up of about 5.2 years found conversion to dementia in 27.0% of population-based studies and 41.5% of clinic-based studies.

People who reach a memory clinic have already been selected — they or someone else was worried enough to pursue it, and they are on average further along. Population-based figures are the better guide to what MCI means as a general finding.

And the direction is not only forward. A meta-analysis of 25 studies found that roughly 24% of people with MCI reverted to normal cognition, with substantial variation by setting and follow-up. One two-year study found 14% reverted, 51% stayed where they were, and 35% progressed.

A meaningful share of people with MCI do progress, so plan for that. But the diagnosis is not a final verdict.

Why would it reverse?

Because a number of common, treatable conditions produce cognitive symptoms that look exactly like early dementia — and because the testing captured a bad moment.

Several things cause measurable cognitive impairment and are correctable:

• Depression. It is common and treatable, and higher baseline depressive symptoms have been found to predict reversion to normal cognition. Depression in older adults frequently shows up as cognitive complaints rather than as visible sadness.
• Sleep apnea. Fragmented sleep and nighttime oxygen dips produce daytime attention and memory problems. It is widespread and widely undiagnosed.
• Vitamin B12 deficiency, and other nutritional deficiencies.
• Thyroid dysfunction, especially underactive.
• Medications. Anticholinergics, benzodiazepines and sedating sleep aids all impair cognition, and older adults are frequently on more than one without anyone having totaled the load.
• Uncorrected hearing and vision loss, which degrade the input and then get measured as impaired processing.
• Alcohol, at levels people do not think of as a problem.
• Acute illness, pain, or recent hospitalization at the time of testing.

Factors associated with reverting include higher education, larger hippocampal volume, less functional impairment, greater complex mental activity, and better vision and sense of smell. Reversion is less likely with multi-domain MCI, with a moderately or severely impaired domain, and when the memory complaint comes from a family member rather than the person themselves.

What should be ruled out before accepting the label?

A short list of blood tests, a hard look at the medication list, and an honest conversation about mood and sleep.

Check that these have been done, and ask for them if not:

• Blood work: B12, folate, thyroid function, metabolic panel, and depending on the picture, calcium and liver and kidney function.
• A medication review, specifically for anticholinergic burden and sedatives. Ask the pharmacist, not only the doctor.
• Screening for depression, taken seriously rather than dismissed as an understandable reaction to the diagnosis.
• A question about snoring and daytime sleepiness, and a sleep study if there is any suggestion of apnea.
• A hearing test and an eye exam, both current.
• Repeat testing after several months. A single set of scores is a snapshot taken on one day, and a bad day is a real phenomenon. Serial testing is far more informative than one result.

If none of that has happened, treat the diagnosis as provisional.

What about the new blood tests?

They can tell you whether Alzheimer's pathology is present. They cannot tell you when, or whether, someone will develop dementia.

Blood biomarker tests for Alzheimer's are now clinically available and are an advance over the older path of a spinal tap or a PET scan.

They answer one question: is there evidence of Alzheimer's pathology in this brain. That is useful — it can distinguish Alzheimer's-driven MCI from MCI caused by something else entirely, and it matters if disease-modifying treatment is being considered, since eligibility depends on confirming amyloid.

A positive result does not tell you the timeline, and some people with Alzheimer's pathology never develop dementia in their lifetime. Before testing, it is worth asking what you would do differently depending on the result and whether you want to know.

What actually helps at this stage?

Exercise has the most consistent evidence. Then the unglamorous list: mood, sleep, hearing, and the vascular risk factors.

There is no drug approved for MCI, and cholinesterase inhibitors are not indicated for it — trials have not shown they prevent progression.

What has evidence behind it:

• Physical exercise, aerobic in particular, which has the most consistent support of anything in this space.
• Treating depression properly, given its association with reversion.
• Treating sleep apnea if it is there.
• Blood pressure control, and management of diabetes and cholesterol. Midlife vascular risk carries into later cognition.
• Hearing aids, worn.
• Complex mental activity — demanding, new activity, which is associated with reversion. Not the same as a puzzle app.
• Social engagement, which is protective and is usually the first thing to shrink after a diagnosis like this.

None of these is a cure, and the effects are modest. They are still the best options available.

What should we do while there is time?

The tasks that require capacity, done now, while she can take part rather than be managed.

These are easier to do now than later.

• The legal documents — durable power of attorney for finances, healthcare proxy, advance directive, and a will if there is not one. Done now, they reflect her actual wishes and are far harder to challenge later.
• The financial picture, mapped while she can explain it. Accounts, passwords, the insurance, what is automatic and what is not.
• The driving conversation, started early and as a plan with a trigger rather than a confrontation.
• What she wants, recorded — about care, about where she wants to live, about what she would and would not accept. In her words, ideally written down or recorded.
• Telling the people who need to know, on her terms, chosen by her.
• A baseline. Get proper neuropsychological testing done now if it has not been. Everything later gets compared against it.

She should be part of these conversations, not talked about after she leaves.